SHARE- BASED COMPENSATION (Tables)
|
6 Months Ended |
Jun. 30, 2025 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
Schedule of Expense Recognized in Financial Statements |
|
|
Six months ended
June 30,
|
|
|
|
2025
|
|
|
2024
|
|
|
|
Unaudited
|
|
|
|
|
|
|
|
|
Share-based compensation - Attributable to equity holders of the Company
|
|
$
|
204
|
|
|
$
|
188
|
|
Share-based compensation - Attributable to non-controlling interests (*)
|
|
|
332
|
|
|
|
811
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
536
|
|
|
$
|
999
|
|
|
Schedule of Number of Share Options |
|
|
2025
|
|
|
2024
|
|
|
|
Number of options
|
|
|
Weighted average exercise prices ($)
|
|
|
Number of options
|
|
|
Weighted average exercise prices ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding on January 1,
|
|
|
594,088
|
|
|
|
18.72
|
|
|
|
397,452
|
|
|
|
28.8
|
|
Granted
|
|
|
213,500
|
|
|
|
1.7
|
|
|
|
13,300
|
|
|
|
7.0
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Forfeited/Expired
|
|
|
(71,986
|
)
|
|
|
45.9
|
|
|
|
(2,938
|
)
|
|
|
121.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding on June 30,
|
|
|
735,602
|
|
|
|
12.3
|
|
|
|
407,814
|
|
|
|
26.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at June 30,
|
|
|
323,683
|
|
|
|
24.7
|
|
|
|
314,648
|
|
|
|
30.7
|
|
|
Schedule of Number of Restricted Stock Units (RSU) |
|
|
2025
|
|
|
2024
|
|
|
|
Number of RSUs
|
|
|
Weighted average grant date fair value
|
|
|
Number of RSUs
|
|
|
Weighted average grant date fair value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding on January 1,
|
|
|
19,806
|
|
|
|
11.87
|
|
|
|
41,420
|
|
|
|
12.4
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
1,300
|
|
|
|
9.7
|
|
Vested
|
|
|
(4,991
|
)
|
|
|
15.7
|
|
|
|
(7,127
|
)
|
|
|
14.8
|
|
Forfeited/Expired
|
|
|
(2,135
|
)
|
|
|
12.0
|
|
|
|
(112
|
)
|
|
|
7.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding on June 30,
|
|
|
12,680
|
|
|
|
10.4
|
|
|
|
35,481
|
|
|
|
11.8
|
|
|
Schedule of Compensation Cost of Equity-Based Awards |
|
|
Six months ended
June 30,
|
|
|
|
|
2025 (*)
|
|
|
|
2024 (*)
|
|
|
|
Unaudited
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
$
|
22
|
|
|
$
|
15
|
|
Research and development, net
|
|
|
155
|
|
|
|
213
|
|
Sales and marketing
|
|
|
71
|
|
|
|
129
|
|
General and administrative
|
|
|
224
|
|
|
|
260
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
472
|
|
|
$
|
617
|
|
|
Employees Consultants and Directors [Member] |
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
Schedule of Assumptions Used to Value Options |
|
|
2025
|
|
2024
|
|
|
|
|
|
|
|
Dividend yield (%)
|
|
-
|
|
-
|
|
Expected volatility of the share prices (%)
|
|
55
|
|
54
|
|
Risk-free interest rate (%)
|
|
4.46
|
|
4.21-4.24
|
|
Suboptimal factor
|
|
1.8-2
|
|
1.8-2
|
|
Post-vesting forfeiture rate (%)
|
|
5-20
|
|
5-20
|
|
|
Subsidiaries’ options granted to employees, directors and consultants [Member] |
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
Schedule of Assumptions Used to Value Options |
|
|
2025
|
|
2024
|
|
|
|
|
|
|
|
Dividend yield (%)
|
|
-
|
|
-
|
|
Expected volatility of the share prices (%)
|
|
76
|
|
79-83
|
|
Risk-free interest rate (%)
|
|
4.29
|
|
3.84-4.79
|
|
Suboptimal factor
|
|
2.0
|
|
1.8-2.0
|
|
Post-vesting forfeiture rate (%)
|
|
8-10
|
|
5-10
|
|
|
Schedule of Number of Restricted Stock Units (RSU) |
|
|
2025
|
|
|
2024
|
|
|
|
Number of options
|
|
|
Weighted average exercise prices ($)
|
|
|
Number of options
|
|
|
Weighted average exercise prices ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding on January 1,
|
|
|
1,718,194
|
|
|
|
2.06
|
|
|
|
2,531,134
|
|
|
|
1.63
|
|
Granted
|
|
|
16,500
|
|
|
|
1.00
|
|
|
|
138,500
|
|
|
|
1.46
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,000
|
)
|
|
|
0.19
|
|
Forfeited/Expired
|
|
|
(63,103
|
)
|
|
|
2.65
|
|
|
|
(748,576
|
)
|
|
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding on June 30,
|
|
|
1,671,591
|
|
|
|
1.57
|
|
|
|
1,916,058
|
|
|
|
2.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at June 30,
|
|
|
1,168,344
|
|
|
|
1.88
|
|
|
|
1,037,638
|
|
|
|
2.01
|
|
|